BioSpring GmbH and Pantherna Therapeutics GmbH, have agreed on a strategic collaboration in the field of research and development and signed a cooperation agreement mid-July.

The long-term PERFECT observational study follows patients from successful Phase I/IIb of ProtheraCytes for the repair and regeneration of damaged cardiac tissues after severe heart attack.

Freudenberg Medical, has expanded its biopharma product portfolio to include custom single-use assemblies which combine Freudenberg’s expertise in silicone extrusion and molding.

Study describes method to successfully modify the functional activity of Spycatcher protein for the rapid generation and high-throughput screening of bispecific antibodies.

Watch our latest video to see how our IntelliXCap Tube Capping/Decapping & Sealing Systems can increase throughput and reduce manual labor in your lab.

Transgene (Euronext Paris: TNG), announces the conversion into equity of 32,999,999.57 euros of debt, drawn down under the outstanding current account advance with its majority shareholder TSGH.